Abstract
This study uses data from the 2010-2018 National Health Interview Survey to characterize trends in human papillomavirus (HPV) vaccination rates, ages at vaccination, and numbers of doses received among young adults in the US between 2010 and 2018.
The human papillomavirus (HPV) vaccine was approved for females in 2006 and males in 2009 for the prevention of anogenital cancer and warts. The indications were expanded in 2020 to include the prevention of oropharyngeal cancer, which is more common in males.1 The Advisory Committee on Immunization Practices recommends routine vaccination with 2 doses at age 11 to 12 years, with catch-up vaccination at age 13 to 26 years (limited to age 13-21 years from 2011 to 2019 for males).2 If the first dose occurs after age 15 years, a 3-dose series is recommended.2
HPV vaccination rates are closely tracked and monitored for adolescents (aged 13-17 years).3 However, little is known about vaccination rates in young adults, who are more likely to make health care decisions for themselves but less likely to access preventive services or be insured.4 Our objective was to assess HPV vaccination among young adults in the US.
Methods
We analyzed data from the 2010-2018 National Health Interview Survey, an annual cross-sectional household survey with face-to-face interviews and a response rate of more than 70% of eligible households.5 We included respondents aged 18 to 21 years, who were asked whether and at what age they were vaccinated and how many doses they received. The primary outcomes were self-reported receipt of any HPV vaccination dose prior to age 21 years and receipt of the first dose between ages 18 and 21 years. In addition, we assessed vaccine series completion (3 doses) for those initiating vaccination between ages 18 and 21 years. Because of the differing timing of recommendations for females and males, outcomes were analyzed by sex. We also assessed trends in receipt of a vaccination dose at any age by year.
National Health Interview Survey weights were used to provide national estimates; the Kendall τ was used to evaluate the trend. Statistical significance was defined as a 2-sided P < .05. Analysis was performed using Stata version 16.1 (StataCorp). This survey was approved by the research ethics review board of the National Center for Health Statistics, and interviewers obtained verbal consent.5
Results
Data on vaccination receipt were available from 93% of respondents aged 18 to 21 years in 2010-2018. The study includes unweighted data from 6606 females (52%) and 6038 males (48%). After weighting, 42% (95% CI, 40%-43%) of females and 16% (95% CI, 15%-18%) of males received at least 1 dose of HPV vaccine at any age. Among females, the percentage increased from 32% (95% CI, 28%-37%) in 2010 to 55% (95% CI, 49%-61%) by 2018 (P = .001) (Table 1). Among males, the percentage increased from 2% (95% CI, 1%-4%) in 2010 to 34% (95% CI, 29%-40%) in 2018 (P < .001).
Table 1. Receipt of at Least 1 Human Papillomavirus Vaccine Dose by Year Among 12 644 Young Adult Women and Men Aged 18-21 Years, 2010-2018.
| Year | Women | Men | ||
|---|---|---|---|---|
| No. vaccinated/totala | % Vaccinated (95% CI)b | No. vaccinated/totala | % Vaccinated (95% CI)b | |
| 2010 | 222/688 | 32.2 (27.9-36.7) | 8/655 | 1.6 (0.6-4.1) |
| 2011 | 350/855 | 42.4 (38.1-46.8) | 24/788 | 2.8 (1.8-4.5) |
| 2012 | 402/914 | 44.6 (40.3-49.0) | 46/770 | 5.4 (3.6-8.1) |
| 2013 | 367/839 | 42.6 (38.1-47.2) | 84/722 | 11.2 (8.5-14.8) |
| 2014 | 358/782 | 47.1 (40.9-53.5) | 122/770 | 16.0 (12.8-19.9) |
| 2015 | 323/692 | 43.1 (38.2-48.2) | 111/626 | 21.1 (16.6-26.3) |
| 2016 | 429/817 | 51.6 (46.4-56.7) | 200/743 | 24.5 (20.4-29.2) |
| 2017 | 352/620 | 54.4 (49.2-59.5) | 191/536 | 34.0 (28.5-39.9) |
| 2018 | 217/399 | 55.2 (49.4-60.9) | 143/428 | 34.1 (28.5-40.0) |
Unweighted.
Weighted percentage and 95% CI.
Among 6606 females, 254 (weighted, 4% [95% CI, 3%-4%]) received their first HPV vaccination between ages 18 and 21 years (Table 2). Among 6038 males, 162 (weighted, 3% [95% CI, 2%-3%]) received their first dose between ages 18 and 21 years. Of these, 46% (95% CI, 38%-55%) of females and 29% (95% CI, 20%-40%) of males completed the vaccination series.
Table 2. Overall Vaccination Rate Among Young Adults Aged 18-21 Years, Those Who Initiated the Human Papillomavirus Vaccination Between Ages 18 and 21 Years, and Series Completion for Those Who Initiated Vaccination Between Ages 18 and 21 Years.
| Women | Men | |||
|---|---|---|---|---|
| No. vaccinated/totala | % Vaccinated (95% CI)b | No. vaccinated/totala | % Vaccinated (95% CI)b | |
| All respondents aged 18-21 y | ||||
| ≥1 Vaccine dose at any age | 3020/6606 | 41.6 (40.0-43.2) | 929/6038 | 16.2 (14.8-17.7) |
| First dose at age 18-21 y | 254/6606 | 3.8 (3.4-4.3) | 162/6038 | 2.7 (2.3-3.1) |
| Respondents who initiated first dose at age 18-21 y | ||||
| Series completion (3 doses) | 111/254 | 46.3 (37.6-55.2) | 48/162 | 29.1 (20.4-39.7) |
Unweighted.
Weighted percentage and 95% CI.
Discussion
This study found that self-reported HPV vaccination rates for females and males, whether for receipt of a dose at any age or between ages 18 and 21 years, were low, although they increased over time. In comparison, receipt of 1 or more doses among adolescents in 2018 was 68.1%.3 All rates were lower for males than for females. Limitations of the study include its cross-sectional nature, lack of data on dosage timing, and the self-report nature of vaccination data, although adult self-reported HPV vaccination status has previously been shown to be 91% sensitive.6 Possible strategies to improve vaccination uptake and completion among young adults include leveraging university or community vaccination campaigns, especially targeting males, identification of the need for HPV vaccination at the time of influenza vaccination, elimination of cost barriers, and improved education of adult primary care clinicians regarding the risk of HPV-associated cancers, especially in males.
Section Editor: Jody W. Zylke, MD, Deputy Editor.
References
- 1.Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus–attributable cancers—United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019;68(33):724-728. doi: 10.15585/mmwr.mm6833a3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(32):698-702. doi: 10.15585/mmwr.mm6832a3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Elam-Evans LD, Yankey D, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years—United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69(33):1109-1116. doi: 10.15585/mmwr.mm6933a1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Callahan ST, Cooper WO. Changes in ambulatory health care use during the transition to young adulthood. J Adolesc Health. 2010;46(5):407-413. doi: 10.1016/j.jadohealth.2009.09.010 [DOI] [PubMed] [Google Scholar]
- 5.Centers for Disease Control and Prevention . About the National Health Interview Survey. Published June 28, 2019. Accessed September 10, 2020. https://www.cdc.gov/nchs/nhis/about_nhis.htm
- 6.Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors? Vaccine. 2013;31(37):3928-3935. doi: 10.1016/j.vaccine.2013.06.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
